PE20190477A1 - Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos - Google Patents
Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismosInfo
- Publication number
- PE20190477A1 PE20190477A1 PE2019000285A PE2019000285A PE20190477A1 PE 20190477 A1 PE20190477 A1 PE 20190477A1 PE 2019000285 A PE2019000285 A PE 2019000285A PE 2019000285 A PE2019000285 A PE 2019000285A PE 20190477 A1 PE20190477 A1 PE 20190477A1
- Authority
- PE
- Peru
- Prior art keywords
- tcr
- positive
- nucleic acid
- lymphocyte
- antigen recognizing
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 abstract 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 abstract 1
- 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se refiere a un constructo reconocedor de antigenos que comprende una region determinante de la complementariedad (CDR) 3 con una identidad de secuencia SEQ ID N°: 3, 9, 15 siendo capaz de unirse especifica y/o selectivamente a un peptido antigenico COL6A3 y segun su estructura comprende una cadena alfa de TCR; y/o una cadena beta de TCR; una region de cadena variable del TCR con una identidad de secuencia de aminoacidos seleccionadas entre las SEQ ID N°: 4, 10, 16, 22, entre otros; un acido nucleico que codifica dicho constructo reconocedor de antigeno; un vector de expresion que comprende un acido nucleico; una celula hospedadora que puede ser un linfocito T CD4 positivo o CD8 positivo preferentemente. Tambien se refiere a una composicion farmaceutica que comprende el constructo reconocedor de antigeno, el acido nucleico, el vector o la celula hospedadora, y un vehiculo estabilizante y/o excipiente farmaceuticamente aceptables.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376059P | 2016-08-17 | 2016-08-17 | |
| DE102016115246.3A DE102016115246C5 (de) | 2016-08-17 | 2016-08-17 | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| US201662376632P | 2016-08-18 | 2016-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190477A1 true PE20190477A1 (es) | 2019-04-04 |
Family
ID=60419980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000285A PE20190477A1 (es) | 2016-08-17 | 2017-07-04 | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10550182B2 (es) |
| EP (1) | EP3500593B1 (es) |
| JP (2) | JP6964351B2 (es) |
| CN (1) | CN109563149A (es) |
| AU (2) | AU2017312361B2 (es) |
| BR (1) | BR112019001922A2 (es) |
| CA (1) | CA3031995A1 (es) |
| CR (1) | CR20190095A (es) |
| DE (1) | DE102016115246C5 (es) |
| DK (1) | DK3500593T3 (es) |
| LT (1) | LT3500593T (es) |
| MA (1) | MA45976B1 (es) |
| MX (1) | MX2019001769A (es) |
| PE (1) | PE20190477A1 (es) |
| RS (1) | RS62498B1 (es) |
| SG (1) | SG11201900955VA (es) |
| TW (1) | TWI775768B (es) |
| WO (1) | WO2018033291A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| ZA201900664B (en) * | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| SG11201908527SA (en) * | 2017-03-15 | 2019-10-30 | Hutchinson Fred Cancer Res | High affinity mage-a1-specific tcrs and uses thereof |
| KR20200047660A (ko) | 2017-09-01 | 2020-05-07 | 다나-파버 캔서 인스티튜트 인크. | 암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드 |
| DE102017125888A1 (de) | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| CN118324918A (zh) | 2017-11-06 | 2024-07-12 | 伊玛提克斯生物技术有限公司 | 新型改造t细胞受体及其免疫治疗的应用 |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| CN113412277A (zh) * | 2019-01-22 | 2021-09-17 | 美国卫生和人力服务部 | 针对含有g12r突变的ras的hla第ii类限制性t细胞受体 |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| EA202193139A1 (ru) | 2019-05-27 | 2022-03-01 | Имматикс Юс, Инк. | Вирусные векторы и их применение в адоптивной клеточной терапии |
| CA3142386A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN116096740A (zh) * | 2020-06-09 | 2023-05-09 | 得克萨斯州大学系统董事会 | 经改造t细胞受体和使用方法 |
| TW202227616A (zh) | 2020-08-21 | 2022-07-16 | 美商英麥提克斯股份有限公司 | 分離ｃｄ８＋選擇ｔ細胞的方法 |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| MX2023007817A (es) | 2020-12-31 | 2023-09-13 | Immatics Us Inc | Polipéptidos de cd8, composiciones y métodos de uso de estos. |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | BMA031 antigen-binding polypeptides |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN117946247B (zh) * | 2023-02-23 | 2024-08-09 | 暨南大学 | 一种识别mage-a3抗原短肽的t细胞受体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| JP2004511425A (ja) | 2000-02-08 | 2004-04-15 | ザ ペン ステート リサーチ ファウンデーション | 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２ |
| US7820401B2 (en) * | 2004-08-23 | 2010-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Collagen VI and cancer |
| EP1762575A1 (en) * | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| US8105831B2 (en) * | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| US9228007B1 (en) * | 2010-03-11 | 2016-01-05 | The Regents Of The University Of California | Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP3572423B1 (en) * | 2013-07-15 | 2023-12-06 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-human papillomavirus 16 e6 t cell receptors |
| EP3169773B1 (en) * | 2014-07-15 | 2023-07-12 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| EP3753948A1 (en) * | 2014-11-05 | 2020-12-23 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
-
2016
- 2016-08-17 DE DE102016115246.3A patent/DE102016115246C5/de not_active Expired - Fee Related
-
2017
- 2017-07-04 LT LTEPPCT/EP2017/066630T patent/LT3500593T/lt unknown
- 2017-07-04 MA MA45976A patent/MA45976B1/fr unknown
- 2017-07-04 CA CA3031995A patent/CA3031995A1/en active Pending
- 2017-07-04 CR CR20190095A patent/CR20190095A/es unknown
- 2017-07-04 EP EP17739220.6A patent/EP3500593B1/en active Active
- 2017-07-04 DK DK17739220.6T patent/DK3500593T3/da active
- 2017-07-04 AU AU2017312361A patent/AU2017312361B2/en not_active Ceased
- 2017-07-04 RS RS20211327A patent/RS62498B1/sr unknown
- 2017-07-04 SG SG11201900955VA patent/SG11201900955VA/en unknown
- 2017-07-04 WO PCT/EP2017/066630 patent/WO2018033291A1/en unknown
- 2017-07-04 BR BR112019001922A patent/BR112019001922A2/pt not_active IP Right Cessation
- 2017-07-04 MX MX2019001769A patent/MX2019001769A/es unknown
- 2017-07-04 JP JP2019508259A patent/JP6964351B2/ja active Active
- 2017-07-04 PE PE2019000285A patent/PE20190477A1/es unknown
- 2017-07-04 CN CN201780049787.2A patent/CN109563149A/zh active Pending
- 2017-08-11 TW TW106127257A patent/TWI775768B/zh not_active IP Right Cessation
- 2017-08-15 US US15/677,651 patent/US10550182B2/en not_active Expired - Fee Related
-
2018
- 2018-07-13 US US16/035,300 patent/US10526407B2/en active Active
-
2021
- 2021-03-10 AU AU2021201518A patent/AU2021201518A1/en not_active Abandoned
- 2021-08-04 JP JP2021128303A patent/JP2021184729A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201806973A (zh) | 2018-03-01 |
| JP6964351B2 (ja) | 2021-11-10 |
| CA3031995A1 (en) | 2018-02-22 |
| AU2017312361B2 (en) | 2020-12-10 |
| US10526407B2 (en) | 2020-01-07 |
| AU2021201518A1 (en) | 2021-04-01 |
| DE102016115246C5 (de) | 2018-12-20 |
| SG11201900955VA (en) | 2019-03-28 |
| US20180051080A1 (en) | 2018-02-22 |
| BR112019001922A2 (pt) | 2019-07-09 |
| TWI775768B (zh) | 2022-09-01 |
| JP2021184729A (ja) | 2021-12-09 |
| US10550182B2 (en) | 2020-02-04 |
| DK3500593T3 (da) | 2021-11-01 |
| MA45976B1 (fr) | 2021-09-30 |
| CN109563149A (zh) | 2019-04-02 |
| CR20190095A (es) | 2019-06-13 |
| AU2017312361A1 (en) | 2019-02-28 |
| MX2019001769A (es) | 2019-07-08 |
| MA45976A (fr) | 2021-05-19 |
| EP3500593A1 (en) | 2019-06-26 |
| US20180319884A1 (en) | 2018-11-08 |
| LT3500593T (lt) | 2021-11-25 |
| RS62498B1 (sr) | 2021-11-30 |
| EP3500593B1 (en) | 2021-08-25 |
| WO2018033291A1 (en) | 2018-02-22 |
| DE102016115246B3 (de) | 2017-12-14 |
| JP2019528061A (ja) | 2019-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190477A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
| CL2018000124A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer | |
| CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| PE20190335A1 (es) | Receptores de celulas t | |
| PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| PE20171515A1 (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer | |
| EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
| PE20181799A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer microcitico de pulmon y otros tipos de cancer | |
| PE20181800A1 (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer de mama y otros tipos de cancer | |
| EA201992536A1 (ru) | Tcr и пептиды | |
| CR20180295A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
| BR112017013981A2 (pt) | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| CL2019000366A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
| PE20191248A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| AR095432A1 (es) | Proteínas de unión a antígeno | |
| BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
| PE20191617A1 (es) | Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer | |
| EA202090757A1 (ru) | T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53 | |
| CL2019003428A1 (es) | Nuevos péptidos (seq id n°145), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| PE20191711A1 (es) | Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer | |
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) |